viruses isolated in Yokohama during 2007–2008. As a result, it was appeared that **2** completely inhibited the infection of their drug-resistant viruses. Further, the virus inhibition activity of **2** was found to be 20-fold relative to **1**. This unique virus inhibitory action can be utilized to inhibit a broad spectrum of influenza viruses.

doi:10.1016/j.antiviral.2010.02.443

134

Small Molecule Therapeutics of Viruses of Families *Bunyaviridae* and *Arenaviridae*

Marcela Karpuj[1,*], Darci Smith[2], Brenna Kelley-Clarke[3], Andrea Stossel[2], Anna Honko[2], Sean Broce[4], Nessie Van Loan[4], Emma Harrell[4], Colm Kelleher[4], Jaisri R. Lingappa[3], William Hansen[4], Clarence R. Hurt[4], Lisa Hensley[2], Vishwanath R. Lingappa[4]

[1] *CUBRC, Inc., Buffalo, USA;* [2] *Virology Division, USAMRIID, Ft Detrick, USA;* [3] *Department of Global Health, University of Washington, Seattle, USA;* [4] *Prosetta Bioconformatics, Inc., San Francisco, USA*

The nucleoprotein of Rift Valley Fever Virus (RVFV NP), a member of family *Bunyaviridae*, and of Lassa Fever Virus (LASV NP), a member of family *Arenaviridae* both of which have helical capsids, have been expressed in a system for cell-free protein synthesis (CFPS). Assembly was assessed by velocity sedimentation on sucrose density gradients and occurs under conditions previously demonstrated to assemble icosahedral capsid-related structures for multiple virus families. The nucleoprotein assembly pathways of these helical capsid viruses appear distinct from each other as well as from those of the several families of icosahedral capsid viruses studied previously. Preliminary electron microscopic studies confirm an appearance of nucleoprotein assembled by CFPS that is similar to irradiation-inactivated, detergent treated, authentic RVFV and LASV, and markedly different from the structures formed for icosahedral capsid viruses, as would be expected. ELISA screens have been devised for identification of small molecules blocking these assembly pathways. Hits from these screens have been validated by plaque reduction assessment of live virus in cell culture. Partial overlap was observed between the compounds active against RVFV and those active against LASV, with some compounds active against one but not the other, and other compounds active against both. One possible explanation for these findings is that these viral families share a requirement for some host factors. Studies are proceeding on putative host target identification using drug column affinity chromatography of extracts prior to CFPS, on dissection of mechanism of drug action by analysis of the products of CFPS in the presence of compounds, and on structure activity relationship optimization to enhance potency and diminish toxicity.

doi:10.1016/j.antiviral.2010.02.444

135

Efficacy of N-methanocarbathymidine Against Herpes Simplex Virus is Cell Cycle Dependent

Kathy Keith[1,*], Emma Harden[1], Rachel Gill[1], Victor Marquez[2], Earl Kern[1], Mark Prichard[1]

[1] *The University of Alabama School of Medicine, Birmingham, USA;* [2] *National Cancer Institute, Frederick, USA*

(North)-methanocarbathymidine (N-MCT) is a conformationally locked analog of thymidine that is a good inhibitor of herpes simplex virus (HSV) and orthopoxvirus replication in vitro and in vivo. This compound is phosphorylated by the thymidine kinase (TK) encoded by herpes simplex virus and also by the TK homologs encoded by the orthopoxviruses. However, the mechanism of action is complex and other cellular kinases also likely play a role in its metabolic activation in infected and uninfected cells. Isolates of HSV that are resistant to acyclovir are also comparatively resistant to N-MCT which was expected since mutations that reduce TK activity also reduce the activation of both compounds. However, the efficacy of the compound against acyclovir-resistant isolates varied widely depending on the state of the primary human foreskin fibroblast (HFF) cells used in these studies. When HFF cells were seeded 3 days prior to infection, the compound inhibited TK deficient strains of HSV-1 with EC_{50} values of 3–10 μM, but if cells were seeded two days prior to infection the compound was much less effective and had EC_{50} values of 48–66 μM. A similar effect was observed against TK deficient strains of HSV-2. Significant differences were not observed in the efficacy of cidofovir controls. The differential efficacy is likely related to the cell cycle since most of the cells are in the S phase of the cell cycle 2 days after the cells are seeded, and most are in G_1/G_0 by 3 days. It is unclear why the compound would be less effective in dividing cells; it is possible that increased levels of dTTP during S phase might compete with N-MCT triphosphate for incorporation by the viral DNA polymerase. Nonetheless, this observation is intriguing and could potentially be useful as the antiviral and the antitumor properties of this compound are of significant interest.

Acknowledgement: Supported by contract N01-AI-30049 from the NIAID, NIH.

doi:10.1016/j.antiviral.2010.02.445

136

Synthesis and Antiviral Activity of Adamantyl Modified Nucleoside Phosphonates: Analogs of Cidofovir

Yuri Klimochkin*, Alexander Reznikov, Michael Skomorokhov, Eugene Golovin

Samara State Technical University, Samara, Russia

Cidofovir (HPMPC, CDV, 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine) is a potent and selective anti-DNA virus agent. Cidofovir suppresses the in vitro growth of all human and animal DNA viruses thus for examined. In the ongoing search for new cidofovir analogues and derivatives, accruing attention is given to the development of neutral ester prodrugs to enhance oral absorption and improve pharmacological parameters. In the paper, we described the synthesis of novel nucleoside phosphonates modified by adamantyl moiety: R = $AdCH_2$, $AdCH_2CH_2$, $AdCH_2CH_2CH_2$, $AdOCH_2CH_2$, $AdOCH_2CH_2CH_2$, $AdOCH_2CH_2CH_2CH_2$, $AdOCH_2CH_2OCH_2CH_2$, 3-Et-$AdCH_2$, 3-Et-$AdCH_2CH_2$, 3-Et-$AdCH_2CH_2CH_2$, 3-Et-$AdOCH_2CH_2$, 3-Et-$AdOCH_2CH_2CH_2$, 3-Et-$AdOCH_2CH_2CH_2CH_2$, 3-Et-$AdOCH_2CH_2OCH_2CH_2$. This way of modification could allow developing new therapeutic agents having high level of bioavailability and can be able to act on two or more stages of reproductive cycle of DNA viruses.

Acknowledgments: The research was supported by the Russian Federal Agency on Science and Innovations and Russian Federal Education Agency (02.552.11.7077, 02.740.11.0394 and P706 (12.08.2009).